I've only owned AVXL a few months, but I've never seen a stock where more posters want to fire the CEO. The one news item that crops up weekly, sometimes almost every day when you hit the headline link here is, the Gross Law firm gathering stock owners for a class action suit. I really don't know how they do it, you can cure cancer and get a headline for a day, keep announcing you're suing the company and it shows all the time. Anyway my point is that companies and their CEO's get flak all the time while they don't have an approved product for sale. On approval these very same people will be toasted for their brilliance.
AVXL's market cap is much smaller than NWBO, but market cap doesn't put you on a major stock exchange, stock price does and while it's down some on recent news, it's well above the minimum for maintaining an Nasdaq listing. Like NWBO they're in peer review for a Journal article, and it seems to be taking forever. I frankly forget how many months our initial Journal article took, or just how many months Nature has been working on the next one.
My point is only that all companies where products are slow to approval get criticism and frankly it's progress that limits it, then approval, without that CEO's get raked over the coals regardless of whether they issue PR's, have quarterly webcasts, etc. LP probably gets less flak from us than Missling, AVXL's CEO, does, and he does quarterly conference calls, etc. I believe that both companies will be successful in time. I like NWBO's potential more, but if AVXL can play a roll in Alzheimer's, Parkinson's, RETT's, etc it too could be huge. I believe NWBO's success will come first, but in time AVXL's success will come, and it won't matter if they replace the CEO or not.
Gary
